ArticleCancer cell international2026
Global landscape of protein-coding and long non-coding RNA alternative splicing and regulation in the human esophageal squamous cell carcinoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAberrant alternative splicing (AS) generates multiple isoforms from a single gene, leading to functional diversity and potentially contributing to tumorigenesis. The spliceosome pathway is significantly activated in esophageal squamous cell carcinoma (ESCC). However, the functional implications and drug-response relevance of protein-coding and long non-coding RNA (lncRNA) AS and splicing factors (SFs) have not been fully characterized in ESCC.
methodsThe transcriptomic data (PRJNA533799, PRJNA435587, PRJNA704753, PRJNA489250, PRJNA298963) from Gene Expression Omnibus (GEO) database were used to summarize the AS landscape by rMATS analysis. Weighted correlation network analysis (WGCNA) and motif enrichment analysis were performed to investigate biological processes of AS events and SFs. The relationship between AS and drug sensitivity was explored by Spearman correlation analysis.
resultsA total of 3699 differential alternative splicing events (DASEs) were identified, predominantly involving protein-coding RNA and lncRNA (96.65%). The DASEs and SFs were primarily involved in biological processes such as the cell cycle, immune response, metabolism, metastasis, and apoptosis. Moreover, 85 RNA binding proteins were identified as dysregulated and hub SFs to modulate AS in ESCC. Notably, Bortezomib and BI-2536 were sensitive in inhibiting ESCC cell proliferation, correlating strongly with the DASEs and SFs.
conclusionOur research globally summarized the dysregulation of AS and SF, their associated biological effects, and recommended combined drug treatment strategies for ESCC. This study improves our knowledge of the molecular features of ESCC, supports the development of innovative therapies, and further advances fundamental research on precision medicine for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.